Core Viewpoint - Fuhong Hanlin (02696) has seen its stock price increase by over 24% in February, with a recent rise of 5.67% to HKD 70.85, driven by a strategic partnership with Eisai Co., Ltd for the commercialization of the anti-PD-1 antibody, Surufatinib, in Japan [1] Group 1: Partnership Details - Eisai and Fuhong Hanlin have entered into an exclusive commercialization agreement for Surufatinib in Japan, which includes a USD 75 million upfront payment, potential regulatory milestone payments up to USD 80.01 million, and sales milestone payments up to USD 233.3 million [1] - Fuhong Hanlin will also receive a double-digit percentage royalty based on product sales [1] Group 2: Strategic Decisions - Fuhong Hanlin's CEO, Dr. Zhu Jun, indicated that the company has been strategically preparing for the Japanese market for three years, initially planning to independently launch and commercialize the product [1] - The decision to partner with Eisai was influenced by the "very sincere" offer made by Eisai, leading to a shift from their original plan [1]
复宏汉霖再涨超6% 月内涨超24% 公司将斯鲁利单抗日本权益授权给卫材